Literature DB >> 1787639

Primary hyperoxaluria: therapeutic strategies for the 90's.

J I Scheinman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1787639     DOI: 10.1038/ki.1991.224

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  8 in total

1.  Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.

Authors:  Jon I Scheinman; Paul A Voziyan; John M Belmont; Sergei V Chetyrkin; Daniel Kim; Billy G Hudson
Journal:  Urol Res       Date:  2005-11-15

2.  Initial manifestation of primary hyperoxaluria type I in adults-- recognition, diagnosis, and management.

Authors:  J J Kuiper
Journal:  West J Med       Date:  1996-01

3.  Liver transplantation in oxalosis prior to advanced chronic kidney disease.

Authors:  Jon I Scheinman
Journal:  Pediatr Nephrol       Date:  2010-07-29       Impact factor: 3.714

4.  Primary hyperoxaluria type 1--liver transplantation before end-stage renal disease?

Authors:  J I Scheinman
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

Review 5.  ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis.

Authors:  T M Reynolds
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 6.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

Review 7.  Should liver transplantation be performed before advanced renal insufficiency in primary hyperoxaluria type 1?

Authors:  P Cochat; K Schärer
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

8.  Primary hyperoxaluria Type 1: A case report in an extended family with a novel AGXT gene mutation.

Authors:  Mohamed W Abukhatwah; Samia H Almalki; Mohammed S Althobaiti; Abdulla O Alharbi; Najla K Almalki; Naglaa M Kamal
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.